Anti-D Rh0 immunoglobulin - Kamada

Drug Profile

Anti-D Rh0 immunoglobulin - Kamada

Alternative Names: Anti-D immunoglobulin - Kamada; KamRho; KamRho (D) IM; KamRho (D) IV

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kamada
  • Developer Kamada; Vitel Laboratorios
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn; Immune thrombocytopenic purpura

Most Recent Events

  • 09 May 2017 Preregistration for Haemolytic disease of newborn (Prevention) in Mexico (IM)
  • 18 Apr 2017 OncBioMune Pharmaceuticals announces intention to submit MAA to COFEPRIS for haemolytic disease of newborn (Prevention) in April 2017
  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top